Raised full-year EPS guidance by $0.08 to $6.00-$6.10
Agilent reported a strong Q2 FY2026 with revenue and EPS beating guidance, driven by broad-based strength across end markets and significant operating leverage from its Ignite program. Management raised full-year guidance, citing continued momentum and successful mitigation of tariff impacts. Q2 revenue grew 6.3% organically, beating guidance by 80 bps, with EPS of $1.49 coming in 7 cents above the high end.
Buzzberg readRaised full-year EPS guidance by $0.08 to $6.00-$6.10Agilent reported a strong Q2 FY2026 with revenue and EPS beating guidance, driven by broad-based strength across end markets and significant operating leverage from its Ignite program. Management raised full-year guidance, citing continued momentum and successful mitigation of tariff impacts. Q2 revenue grew 6.3% organically, beating guidance by 80 bps, with EPS of $1.49 coming in 7 cents above the high end.Read full analysisCollapse analysis
Agilent reported a strong Q2 FY2026 with revenue and EPS beating guidance, driven by broad-based strength across end markets and significant operating leverage from its Ignite program. Management raised full-year guidance, citing continued momentum and successful mitigation of tariff impacts. Q2 revenue grew 6.3% organically, beating guidance by 80 bps, with EPS of $1.49 coming in 7 cents above the high end.
Operating margin expanded by 130 bps year-over-year to 26.4%, driven by pricing, volume leverage, and structural efficiencies from Ignite.
Full-year revenue growth guidance was raised to 4.5-6% and EPS to $6.00-$6.10, reflecting increased confidence.
Management noted strong growth in pharma (6%), chemical and advanced materials (8%), and diagnostics (11%), with particular strength in forensics and semiconductor-related demand.
Revenue$1.835B
+2% QoQ
EPS$1.49
+10% QoQ
Gross margin54.99%
reported
Op margin21.74%
reported
What changed this quarter
01
Guidance
Raised full-year EPS guidance by $0.08 to $6.00-$6.10
Guidance · revenue to $7.44B
02
Pricing
Pricing contribution exceeded expectations at ~200 bps in Q2
Q2 revenue grew 6.3% organically, beating guidance by 80 bps, with EPS of $1.49 coming in 7 cents above the high end.
03
Supply Chain
Tariffs fully mitigated; playbook built for trade challenges
Operating margin expanded by 130 bps year-over-year to 26.4%, driven by pricing, volume leverage, and structural efficiencies from Ignite.
04
Innovation
China Innovation Center launched, focusing on digital/AI/automation
Full-year revenue growth guidance was raised to 4.5-6% and EPS to $6.00-$6.10, reflecting increased confidence.
AI, capex & demand read
AI
Platform & monetization
Management discussed AI as a key FY26 focus and a potential growth driver, noting pharma customers are using AI to accelerate drug development, which could increase demand for wet lab data and eventually benefit downstream QA/QC workflows. They also plan to deploy AI internally, with more details to come.
Demand
Bookings & conversion
LC and LC-MS instrument growth at low-double digits, replacement cycle tailwind. Management repeatedly emphasized strong execution, broad-based beat, and raised full-year guidance, expressing confidence in continued momentum and the compounding benefits of the Ignite operating system.
Capex
Investment and capacity
Capital expenditure guidance was reduced by $50 million to approximately $450 million for the fiscal year. The company is investing in manufacturing resilience and a new China Innovation Center, including digital/AI/automation capabilities, and completed mechanical construction of Train C for the Advanced Therapeutics Division.
Tone · Upbeat
Management repeatedly emphasized strong execution, broad-based beat, and raised full-year guidance, expressing confidence in continued momentum and the compounding benefits of the Ignite operating system.
Supply-chain alpha
A1
Agilent fully mitigated the impact of initial tariffs through manufacturing moves and price increases, while also expecting further tariff refunds, creating a potential financial upside.
“with the Tariff Task Force achieving full mitigation of the incremental tariffs that began in late spring...fully offset the operating profit impact of these tariffs.”
Agilent is successfully taking market share in the chemical and advanced materials market, which is experiencing robust growth driven by semiconductors and chemical capex.
“Chemical and advanced materials grew a robust 8%. It was fueled by strong semiconductor demand and healthy chemical capex investments in the Americas.”
The diagnostics and clinical business is an enterprise growth opportunity with the new Omnis family ramping well and showing double-digit growth in both instruments and assays.
“The Omnist family continues to ramp very well...we saw double digit growth in both instruments and assays.”